Value of lipocalin 2 as a potential biomarker for bacterial meningitis. (May 2021)

• Record Type: Journal Article
• Authors: Thanh, T.T.; Casals-Pascual, C.; Ny, N.T.H.; Ngoc, N.M.; Geskus, R.; Nhu, L.N.T.; Hong, N.T.T.; Duc, D.T.; Thu, D.D.A.; Uyen, P.N.; Ngoc, V.B.; Chau, L.T.M.; Quynh, V.X.; Hanh, N.H.H.; Thuong, N.T.T.; Diem, L.T.; Hanh, B.T.B.; Hang, V.T.T.; Oanh, P.K.N.; Fischer, R.; Phu, N.H.; Nghia, H.D.T.; Chau, N.V.V.; Hoa, N.T.; Kessler, B.M.; Thwaites, G.; Tan, L.V.
• Is Part Of: Clinical microbiology and infection. Volume 27:Number 5(2021)
• Page Start: 724
• Page End: 730
• Publication Date: 2021-05
• Subjects: Biomarkers -- Central nervous system infections -- Lipocalin 2 -- Mass spectrometry -- Meningitis; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2020.07.006
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Objectives: Central nervous system (CNS) infections are common causes of morbidity and mortality worldwide. We aimed to discover protein biomarkers that could rapidly and accurately identify the likely cause of the infections, essential for clinical management and improving outcome. Methods: We applied liquid chromatography tandem mass spectrometry on 45 cerebrospinal fluid (CSF) samples from a cohort of adults with and without CNS infections to discover potential diagnostic biomarkers. We then validated the diagnostic performance of a selected biomarker candidate in an independent cohort of 364 consecutively treated adults with CNS infections admitted to a referral hospital in Vietnam. Results: In the discovery cohort, we identified lipocalin 2 (LCN2) as a potential biomarker of bacterial meningitis (BM) other than tuberculous meningitis. The analysis of the validation cohort showed that LCN2 could discriminate BM from other CNS infections (including tuberculous meningitis, cryptococcal meningitis and virus/antibody-mediated encephalitis), with sensitivity of 0.88 (95% confident interval (CI), 0.77–0.94), specificity of 0.91 (95% CI, 0.88–0.94) and diagnostic odds ratio of 73.8 (95% CI, 31.8–171.4). LCN2 outperformed other CSF markers (leukocytes, glucose, protein and lactate) commonly used in routine care worldwide. The combination of LCN2, CSF leukocytes, glucose, protein and lactate resulted in the highest diagnostic performance for BM (area under the receiver operating characteristics curve, 0.96; 95% CI, 0.93–0.99). Data are available via ProteomeXchange with identifier PXD020510. Conclusions: LCN2 is a sensitive and specific biomarker for discriminating BM from a broad spectrum of other CNS infections. A prospective study is needed to assess the diagnostic utility of LCN2 in the diagnosis and management of CNS infections.